In wake of Eli Lil­ly set­back, Mer­ck KGaA's lead­ing BTK drug for au­toim­mune dis­ease clears PhI­Ib hur­dle

What kind of fu­ture awaits Bru­ton’s ty­ro­sine ki­nase drugs in au­toim­mune con­di­tions?

A fa­mil­iar play­er in hema­tol­ogy, which at­tract­ed the first big round of in­vest­ment for BTK drugs like ibru­ti­nib that can hit back at ab­nor­mal B cells, re­searchers have been ex­plor­ing un­chart­ed av­enues of drug de­vel­op­ment for au­toim­mune dis­eases. And the po­ten­tial leader in the field, Mer­ck KGaA’s evo­bru­ti­nib, just cleared a big hur­dle in the clin­ic that just might lay the foun­da­tion for a piv­otal ef­fort around mul­ti­ple scle­ro­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.